Is Wegovy Pill Covered by Medicare? The 2026 Answer and What It Means for Your Costs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D explicitly excludes coverage for Wegovy (semaglutide) and all GLP-1 medications prescribed for weight loss under the 2003 Medicare Modernization Act
• The same molecule (semaglutide) is covered when prescribed as Ozempic for type 2 diabetes, creating a coverage paradox based solely on indication
• No Medicare Advantage plan, Medigap policy, or Part D carrier can legally cover Wegovy for weight loss as of April 2026
• The Treat and Reduce Obesity Act, if passed, would change this exclusion, but it has stalled in committee since 2021

Direct answer (40-60 words)

No. Medicare does not cover Wegovy pills or injections for weight loss in 2026. Federal law specifically excludes weight-loss medications from Medicare Part D coverage under the 2003 Medicare Modernization Act. This applies to all Medicare beneficiaries regardless of medical necessity, BMI, or comorbidities. The exclusion extends to all GLP-1 medications when prescribed for obesity.

Table of contents

1. Why Medicare excludes Wegovy: the 2003 law most articles ignore
2. The coverage paradox: same drug, different indication, opposite coverage
3. What "no coverage" actually means in dollar terms
4. The four Medicare coverage scenarios patients ask about most
5. Medicare Advantage plans: can they cover what Original Medicare cannot?
6. The Treat and Reduce Obesity Act: what it would change and why it hasn't passed
7. State-by-state Medicaid coverage (the alternative for dual-eligible patients)
8. Clinical workarounds providers use (and why they backfire)
9. The compounded semaglutide alternative for Medicare patients
10. What most articles get wrong about "medical necessity" exceptions
11. Decision tree: your actual options as a Medicare beneficiary
12. FAQ

Why Medicare excludes Wegovy: the 2003 law most articles ignore

The exclusion starts with Section 1860D-2(e)(2)(A) of the Social Security Act, added by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

The statute reads: "Coverage for a Part D eligible individual under a prescription drug plan or under an MA-PD plan shall not include coverage of a drug when used for the treatment of... weight loss or weight gain."

This is not a coverage decision by CMS. It is not a formulary tier placement. It is a statutory prohibition written into federal law.

Three things matter about this exclusion:

First, it is indication-specific, not molecule-specific. Semaglutide is not banned. Semaglutide prescribed for weight loss is banned. The same pharmacy fills the same molecule for diabetes patients under Medicare coverage and for obesity patients with full out-of-pocket payment.

Second, medical necessity does not override the exclusion. A patient with BMI 42, sleep apnea, type 2 diabetes, and hypertension still cannot get Medicare coverage for Wegovy. The law does not include exceptions for severity, comorbidities, or prior treatment failures.

Third, the exclusion applies to all Part D plans. Every Medicare Part D carrier operates under the same federal statute. No plan can offer Wegovy coverage for weight loss and remain compliant. Patients sometimes ask if switching Part D plans will help. It will not.

The 2003 law also excluded erectile dysfunction drugs, hair growth drugs, and fertility medications. The weight-loss exclusion was added based on cost projections and the perception that obesity treatment was "lifestyle" rather than medical. Congressional Budget Office estimates at the time projected that including weight-loss drugs would add $5 to $10 billion annually to Medicare spending (CBO, 2003).

As of 2026, the exclusion remains unchanged despite multiple legislative attempts to repeal it.

The coverage paradox: same drug, different indication, opposite coverage

Semaglutide exists in two FDA-approved forms for two different indications:

Brand name	Indication	FDA approval	Medicare Part D coverage
Ozempic (injection, 0.5-2 mg weekly)	Type 2 diabetes	2017	Covered (Tier 3 or specialty tier, $200-500/month copay typical)
Rybelsus (pill, 3-14 mg daily)	Type 2 diabetes	2019	Covered (Tier 3 or specialty tier, $150-400/month copay typical)
Wegovy (injection, up to 2.4 mg weekly)	Chronic weight management	2021	Not covered (statutory exclusion)

The molecular difference between Ozempic 2 mg and Wegovy 2.4 mg is a 20% dose increase. The legal difference is total: one is covered, one is prohibited.

This creates three common patient scenarios:

Scenario 1: Patient has obesity and type 2 diabetes. Provider prescribes Ozempic for diabetes. Medicare covers it. Patient loses weight as a secondary effect. This is legal and common. The prescription must be written for diabetes management, not weight loss.

Scenario 2: Patient has obesity without diabetes. Provider prescribes Wegovy for weight management. Medicare does not cover it. Patient pays $1,350 to $1,600 per month out of pocket or discontinues treatment.

Scenario 3: Patient has prediabetes (A1C 5.7-6.4) and obesity. Prediabetes is not an FDA-approved indication for Ozempic. Some providers write the prescription off-label. Medicare may cover it if the provider documents medical necessity for diabetes prevention, but many Part D plans deny these claims on first submission and require prior authorization appeals.

The paradox extends to Rybelsus, the oral semaglutide formulation. Rybelsus is FDA-approved only for type 2 diabetes. There is no FDA-approved oral semaglutide for weight loss as of April 2026. If a provider prescribes Rybelsus off-label for weight management, Medicare will not cover it under the same statutory exclusion.

Patients frequently ask: "Can my doctor just write the prescription for diabetes instead of weight loss?" This is prescription fraud if the patient does not have diabetes. The prescription must match the diagnosis. Medicare audits claims, and providers who systematically misrepresent indications risk exclusion from the program.

What "no coverage" actually means in dollar terms

When Medicare does not cover Wegovy, the patient pays the full retail price set by Novo Nordisk.

Wegovy retail pricing (2026):

Dose	Monthly retail price	Annual cost
0.25 mg starter dose	$1,350	$16,200
0.5 mg	$1,350	$16,200
1.0 mg	$1,430	$17,160
1.7 mg	$1,520	$18,240
2.4 mg maintenance	$1,600	$19,200

These are cash prices at major retail pharmacies (CVS, Walgreens, Walmart). Costco runs $100 to $200 lower per fill but still exceeds $1,200 monthly.

Discount programs that do NOT apply to Medicare patients:

The Novo Nordisk Wegovy Savings Card reduces copays to as low as $25 per month for commercially insured patients. Medicare beneficiaries are statutorily excluded from manufacturer copay assistance under the Anti-Kickback Statute. Offering or accepting the card as a Medicare patient is a federal offense.

GoodRx coupons reduce Wegovy's price to $1,100 to $1,300 per month. Medicare patients can use GoodRx, but doing so means paying entirely out of pocket (the GoodRx transaction does not involve Medicare).

The financial reality for Medicare patients:

A 68-year-old patient on a fixed income with Medicare Part D and a $1,500 monthly Social Security payment cannot afford $1,350 per month for Wegovy. The medication becomes financially inaccessible regardless of medical need.

This is the cost barrier that drives Medicare patients toward compounded semaglutide, off-label Ozempic (if they have diabetes), or discontinuation of GLP-1 therapy entirely.

The four Medicare coverage scenarios patients ask about most

Scenario 1: "I have Medicare Part D and obesity. Can I get Wegovy covered if my doctor says it's medically necessary?"

No. Medical necessity does not override the statutory exclusion. Even with documented BMI over 40, cardiovascular disease, sleep apnea, and failed prior weight-loss attempts, Medicare cannot cover Wegovy for weight management. The law does not include a medical necessity exception.

Scenario 2: "I have Medicare and type 2 diabetes. Can I get Ozempic covered and lose weight with it?"

Yes. Ozempic is covered under Part D for type 2 diabetes management. Weight loss is a known effect of the medication. Your provider writes the prescription for diabetes, Medicare processes it as a diabetes medication, and you pay the specialty tier copay (typically $200 to $500 per month depending on your plan). This is the most common path for Medicare patients to access semaglutide.

Scenario 3: "I'm on Medicare and my doctor prescribed Wegovy. The pharmacy says it's not covered. Is there an appeal process?"

You can appeal, but the appeal will be denied. The exclusion is statutory, not a plan-specific coverage decision. Part D plans have no authority to override federal law. The appeals process (redetermination, reconsideration, ALJ hearing) applies to coverage decisions within the plan's discretion. Weight-loss medication exclusion is outside that discretion.

Scenario 4: "I have a Medicare Advantage plan that advertises 'enhanced drug coverage.' Does that include Wegovy?"

No. Medicare Advantage plans must follow the same Part D statutory exclusions as standalone Part D plans. Enhanced coverage typically means lower copays for covered drugs or coverage of some over-the-counter items. It does not mean coverage of statutorily excluded categories. No MA plan can legally cover Wegovy for weight loss.

Medicare Advantage plans: can they cover what Original Medicare cannot?

Medicare Advantage (Part C) plans are private insurance plans that contract with Medicare to provide Part A, Part B, and usually Part D benefits.

The question patients ask: "Can my Advantage plan add Wegovy as a supplemental benefit?"

The short answer: No.

Medicare Advantage plans can offer supplemental benefits not covered by Original Medicare (dental, vision, gym memberships, over-the-counter allowances). But Part D prescription drug coverage within an MA-PD plan must follow the same statutory exclusions as standalone Part D plans.

The relevant regulation is 42 CFR 423.100, which defines Part D drugs and incorporates the exclusions from Section 1860D-2(e) of the Social Security Act. MA-PD plans have no authority to cover excluded drug categories.

What about Special Supplemental Benefits for the Chronically Ill (SSBCI)?

Starting in 2020, CMS allowed MA plans to offer SSBCI to enrollees with chronic conditions. These benefits can include items and services not traditionally covered by Medicare if they are "used to diagnose, prevent, or treat an illness or injury" and have a "reasonable expectation of improving or maintaining the health or overall function" of the enrollee (CMS, 2019).

Some MA plans have explored whether SSBCI could cover weight-loss medications. As of 2026, CMS has not issued guidance permitting this, and no major MA carrier has added Wegovy as an SSBCI benefit. The statutory Part D exclusion appears to take precedence.

The pattern we see in Medicare Advantage prior authorization requests:

Providers submit prior authorization requests for Wegovy under MA-PD plans, often arguing that obesity with comorbidities qualifies as a chronic illness under SSBCI. These requests are denied with the same statutory exclusion language. The denial letter typically reads: "This medication is excluded from Medicare Part D coverage under Section 1860D-2(e)(2)(A) when used for weight loss."

MA plans cannot override this exclusion without explicit CMS regulatory change.

The Treat and Reduce Obesity Act: what it would change and why it hasn't passed

The Treat and Reduce Obesity Act (TROA) is a bipartisan bill introduced in every Congress since 2013. It has never passed.

What TROA would do:

1. Remove the statutory exclusion for weight-loss medications from Medicare Part D.
2. Require Part D plans to cover FDA-approved obesity medications when prescribed by an enrolled Medicare provider.
3. Expand Medicare coverage for intensive behavioral therapy for obesity from primary care providers to include other qualified practitioners.

Current status (April 2026):

The bill was reintroduced in the 119th Congress as S. 2407 (Senate) and H.R. 4818 (House). It has 23 Senate cosponsors and 87 House cosponsors. It has been referred to the Senate Finance Committee and House Energy and Commerce Committee. It has not received a committee vote.

Why it stalls:

The Congressional Budget Office scored the 2023 version of TROA at $34.6 billion in additional Medicare spending over 10 years (CBO, 2023). This assumes 10% of eligible Medicare beneficiaries (approximately 3.7 million people) would use covered obesity medications at an average annual cost of $9,400 per patient.

The bill stalls on cost. Medicare's Part D program is already projected to face insolvency pressures. Adding $3 to $4 billion annually in obesity medication spending requires either premium increases, general revenue transfers, or offsets elsewhere in the Medicare budget.

What would change if TROA passed:

Part D plans would be required to cover Wegovy, Saxenda, Zepbound, and other FDA-approved obesity medications. Plans could still place them on high tiers (specialty tier with 25-33% coinsurance is likely). Patients would pay copays in the $300 to $600 per month range instead of $1,350 to $1,600 full retail.

Prior authorization would still apply. Plans would require documentation of BMI over 30 (or over 27 with comorbidities), prior weight-loss attempts, and ongoing lifestyle modification.

The Novo Nordisk savings card would still not apply to Medicare patients under the Anti-Kickback Statute.

Prediction: TROA will not pass in the 119th Congress without significant Medicare financing reform or a narrower bill that limits coverage to patients with obesity and established cardiovascular disease (a smaller, more defensible population). The cost barrier remains the primary obstacle.

State-by-state Medicaid coverage (the alternative for dual-eligible patients)

Patients who qualify for both Medicare and Medicaid (dual-eligible) have a different coverage landscape.

Medicaid is not subject to the Medicare Part D statutory exclusion. Each state sets its own Medicaid formulary. Some states cover GLP-1 medications for weight loss. Most do not.

States that cover Wegovy under Medicaid (as of April 2026):

• None cover Wegovy without restrictions.
• 14 states cover GLP-1s for obesity with prior authorization requiring BMI over 35 with comorbidities or BMI over 40.
• 36 states exclude GLP-1s for weight loss entirely.

Dual-eligible coverage rules:

For dual-eligible patients, Medicare Part D is the primary payer for prescription drugs. Medicaid is secondary. If Medicare excludes a drug category, Medicaid can cover it, but only if the state's Medicaid program includes it on formulary.

Example: A 66-year-old patient has Medicare Part D and also qualifies for Medicaid in North Carolina. North Carolina Medicaid does not cover Wegovy for weight loss. The patient has no coverage path and pays full retail or uses an alternative.

Example 2: A 70-year-old patient has Medicare and Medicaid in Louisiana. Louisiana Medicaid covers Wegovy with prior authorization for BMI over 35 with type 2 diabetes or cardiovascular disease. Medicaid becomes the payer. The patient's copay is $0 to $3 (typical Medicaid copay structure).

The dual-eligible advantage:

Dual-eligible patients in states with Medicaid GLP-1 coverage have access Medicare-only patients do not. This creates a coverage cliff: patients with slightly higher income who qualify for Medicare but not Medicaid lose access entirely.

Checking your state's Medicaid formulary is the first step for dual-eligible patients. The formulary is published on your state Medicaid website under "Preferred Drug List" or "Pharmacy Benefits."

Clinical workarounds providers use (and why they backfire)

Providers who want to help Medicare patients access semaglutide sometimes attempt workarounds. These workarounds carry compliance risk and often fail.

Workaround 1: Writing Ozempic for prediabetes.

Prediabetes (A1C 5.7 to 6.4) is not an FDA-approved indication for Ozempic. Some providers write the prescription off-label, arguing diabetes prevention is a legitimate medical use.

Why it backfires: Medicare Part D plans deny many of these claims. The plan's pharmacy benefit manager flags the diagnosis code (prediabetes) as not matching the FDA-approved indication (type 2 diabetes). The claim is rejected. The provider can appeal, but success rates are low. If the appeal succeeds, the plan may audit the provider's prescribing patterns and request documentation for all similar claims.

Workaround 2: Diagnosing type 2 diabetes when the patient has prediabetes or obesity alone.

This is fraud. Intentionally misrepresenting a diagnosis to obtain insurance coverage violates the False Claims Act. Providers who engage in systematic upcoding face exclusion from Medicare, civil monetary penalties, and potential criminal prosecution.

Medicare's Unified Program Integrity Contractors (UPICs) audit claims data for patterns of inappropriate diagnosis coding. A provider who prescribes Ozempic to 50 patients and codes all of them with type 2 diabetes when lab results show prediabetes or normal glucose will trigger an audit.

Workaround 3: Prescribing Rybelsus (oral semaglutide) off-label for weight loss.

Rybelsus is FDA-approved only for type 2 diabetes. Prescribing it for weight management is off-label. Medicare will not cover off-label use of a medication when the off-label indication falls into a statutorily excluded category (weight loss).

The claim is denied with the same exclusion language as Wegovy.

Workaround 4: Using a diagnosis of "metabolic syndrome" instead of obesity.

Metabolic syndrome is a cluster of conditions (high blood pressure, high blood sugar, excess abdominal fat, abnormal cholesterol). It is not an FDA-approved indication for any GLP-1 medication.

Medicare Part D plans deny these claims. The diagnosis code for metabolic syndrome does not map to an FDA-approved indication for semaglutide.

The compliance principle:

The prescription must match a legitimate, documented diagnosis that corresponds to an FDA-approved or widely accepted off-label indication not excluded by statute. Obesity and weight loss are excluded. Type 2 diabetes is not. The line is clear.

Providers who help patients navigate this honestly (explaining that Ozempic is covered for diabetes, Wegovy is not covered for weight loss, and the patient must meet diagnostic criteria for diabetes to qualify) stay compliant. Providers who creatively reinterpret diagnoses to bypass the exclusion assume significant legal risk.

The compounded semaglutide alternative for Medicare patients

Compounded semaglutide is the most common alternative for Medicare patients who cannot afford Wegovy's retail price and do not have type 2 diabetes.

Pricing:

• FormBlends compounded semaglutide: $179 to $279 per month (no insurance)
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

Key differences from Wegovy:

• Compounded semaglutide is not FDA-approved.
• It is prepared by a state-licensed 503A or 503B compounding pharmacy.
• It is drawn from a vial with a syringe rather than delivered by a pre-filled pen.
• It is not covered by Medicare (compounded drugs are generally excluded from Part D unless the FDA-approved version is unavailable).

Medicare patients can pay cash for compounded semaglutide. There is no legal prohibition. The patient pays out of pocket, the compounding pharmacy dispenses the medication, and Medicare is not involved.

When compounded semaglutide makes sense for Medicare patients:

• You have obesity without diabetes.
• You cannot afford $1,350+ per month for Wegovy.
• You are comfortable with a non-FDA-approved compounded medication.
• You can self-inject from a vial.

When it does not make sense:

• You have type 2 diabetes and qualify for Medicare-covered Ozempic (copay $200-500 is likely cheaper than $279/month compounded, and you get an FDA-approved product).
• You strongly prefer FDA-approved medications.
• You are not comfortable with injection technique.

The clinical pattern we see:

Medicare patients who start compounded semaglutide tend to stay on it long-term if they tolerate it well. The predictable monthly cost ($179 to $279) is manageable on a fixed income in a way that $1,350 is not. Patients who develop side effects or prefer the convenience of a pre-filled pen sometimes switch to Ozempic if they can establish a diabetes diagnosis, or they discontinue GLP-1 therapy.

The compounded option does not solve the coverage problem. It bypasses it.

What most articles get wrong about "medical necessity" exceptions

Many articles on Medicare GLP-1 coverage state: "Medicare may cover Wegovy if your doctor documents medical necessity."

This is false.

The error:

Medical necessity is a standard Medicare applies to determine whether a covered service or drug is appropriate for a patient's condition. It does not override statutory exclusions.

Example: Medicare covers knee replacement surgery. If your doctor documents that your knee osteoarthritis is severe enough to warrant surgery, Medicare pays for it (medical necessity satisfied). If your doctor documents that you want knee replacement for cosmetic reasons, Medicare denies it (medical necessity not satisfied).

But medical necessity only applies within the universe of coverable services. Weight-loss medications are outside that universe by statute.

The correct statement:

Medicare cannot cover Wegovy for weight loss regardless of medical necessity. The exclusion is categorical. A patient with BMI 50, heart failure, sleep apnea, and diabetes does not get an exception. The law does not include a severity threshold or medical necessity override.

Why this error persists:

Many articles are written by non-specialists who conflate "coverage denial due to lack of medical necessity" with "coverage denial due to statutory exclusion." These are different mechanisms.

A Part D plan can deny Ozempic for a patient with type 2 diabetes if the patient has not tried metformin first (lack of medical necessity under the plan's step therapy protocol). The patient can appeal by providing documentation of metformin intolerance.

A Part D plan must deny Wegovy for weight loss because the statute prohibits coverage. No amount of documentation changes the outcome.

The test:

If the question is "Will Medicare cover this?" ask: "Is this drug category statutorily excluded?" If yes, medical necessity is irrelevant. If no, medical necessity determines coverage within the plan's criteria.

Weight loss is excluded. Medical necessity does not apply.

Decision tree: your actual options as a Medicare beneficiary

Start here: Do you have type 2 diabetes (A1C ≥ 6.5% or fasting glucose ≥ 126 mg/dL on two occasions)?

→ Yes: Your provider can prescribe Ozempic or Rybelsus for diabetes management. Medicare Part D covers it. Expect $200 to $500 per month copay (specialty tier). Weight loss is a secondary benefit. This is the standard coverage path.

→ No, but I have prediabetes (A1C 5.7-6.4): Ozempic is not FDA-approved for prediabetes. Some providers prescribe it off-label. Medicare may deny the claim. If you want to try, ask your provider to submit prior authorization with documentation of diabetes risk factors. Approval is inconsistent across plans.

→ No, I have obesity without diabetes or prediabetes: Medicare will not cover Wegovy or any GLP-1 for weight loss. Your options:

Option A: Pay cash for Wegovy.

• Cost: $1,350 to $1,600 per month.
• Use GoodRx to reduce to $1,100 to $1,300.
• This is financially unsustainable for most Medicare patients.

Option B: Use compounded semaglutide.

• Cost: $179 to $279 per month (FormBlends pricing).
• Not FDA-approved.
• Requires self-injection from a vial.
• No Medicare involvement (you pay cash, pharmacy dispenses).

Option C: Check if you qualify for Medicaid (dual-eligible).

• If your income is low enough to qualify for Medicaid, check your state's Medicaid formulary.
• 14 states cover GLP-1s for obesity with prior authorization.
• If your state covers it, Medicaid pays. Your copay is $0 to $3.

Option D: Wait for TROA to pass.

• The Treat and Reduce Obesity Act would require Medicare to cover obesity medications.
• It has not passed in 13 years.
• Do not wait for this if you need treatment now.

Option E: Pursue non-GLP-1 weight-loss treatments.

• Medicare covers bariatric surgery for BMI ≥ 35 with comorbidities.
• Medicare covers intensive behavioral therapy for obesity (up to 22 sessions per year).
• Other FDA-approved weight-loss medications (phentermine/topiramate, naltrexone/bupropion) are also excluded under the same statute.

The decision most Medicare patients make:

Patients with diabetes use Ozempic through Medicare. Patients without diabetes either pay for compounded semaglutide or do not use GLP-1 therapy. Very few Medicare patients pay $1,350/month for Wegovy long-term.

FAQ

Does Medicare cover Wegovy pills? No. There is no pill form of Wegovy. Wegovy is an injectable semaglutide approved for weight management. Medicare does not cover it under the statutory exclusion for weight-loss medications. Rybelsus is the oral semaglutide pill, approved only for type 2 diabetes, and Medicare covers it for that indication.

Does Medicare cover Wegovy injections for weight loss? No. Medicare Part D excludes all medications used for weight loss under Section 1860D-2(e)(2)(A) of the Social Security Act. This applies to Wegovy, Saxenda, Zepbound, and all other FDA-approved obesity medications.

Can I get Wegovy covered if I have obesity and heart disease? No. Comorbidities do not override the statutory exclusion. Medicare cannot cover Wegovy for weight management regardless of cardiovascular disease, sleep apnea, diabetes, or other conditions.

Does Medicare cover Ozempic for weight loss? No. Ozempic is covered only when prescribed for its FDA-approved indication: type 2 diabetes. If your provider writes the prescription for weight loss, Medicare will deny the claim under the same exclusion that applies to Wegovy.

Will my Medicare Advantage plan cover Wegovy? No. Medicare Advantage plans must follow the same Part D statutory exclusions as standalone Part D plans. No MA plan can legally cover Wegovy for weight loss.

Can I appeal if Medicare denies my Wegovy prescription? You can file an appeal, but it will be denied. The exclusion is statutory, not a plan-specific coverage decision. Appeals apply to coverage decisions within the plan's discretion. Weight-loss exclusions are outside that discretion.

Does the Wegovy savings card work with Medicare? No. Federal law prohibits Medicare beneficiaries from using manufacturer copay assistance cards. Offering or accepting the card as a Medicare patient violates the Anti-Kickback Statute.

What is the cheapest way for a Medicare patient to get semaglutide? If you have type 2 diabetes, Ozempic through Medicare Part D (copay $200-500/month) is the cheapest FDA-approved option. If you do not have diabetes, compounded semaglutide ($179-279/month cash pay) is the most affordable alternative.

Does Medicaid cover Wegovy if I have both Medicare and Medicaid? It depends on your state. Medicaid is secondary to Medicare for prescription drugs. If your state Medicaid program covers GLP-1s for obesity, Medicaid may pay after Medicare denies. Only 14 states cover GLP-1s for weight loss as of 2026.

Will Medicare ever cover Wegovy? Only if Congress passes the Treat and Reduce Obesity Act or similar legislation to remove the statutory exclusion. The bill has been introduced in every Congress since 2013 and has not passed. No regulatory change by CMS can override the statute.

Can my doctor prescribe Ozempic instead of Wegovy to get around the coverage issue? Only if you have type 2 diabetes. Prescribing Ozempic for weight loss when you do not have diabetes is off-label use of a medication for a statutorily excluded indication. Medicare will deny the claim. Intentionally misrepresenting your diagnosis is fraud.

Is compounded semaglutide covered by Medicare? No. Compounded medications are generally excluded from Part D coverage unless the FDA-approved version is unavailable. Patients pay cash for compounded semaglutide without Medicare involvement.

Sources

1. Social Security Act, Section 1860D-2(e)(2)(A). Exclusions from Part D Coverage. 2003.
2. Congressional Budget Office. Cost Estimate for H.R. 1 (Medicare Prescription Drug, Improvement, and Modernization Act of 2003). November 2003.
3. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drugs and Formulary Requirements. 42 CFR 423.100. 2024.
4. Congressional Budget Office. Cost Estimate for S. 2407 (Treat and Reduce Obesity Act of 2023). May 2023.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
6. Centers for Medicare & Medicaid Services. Medicare and Medicaid Programs; Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Programs of All-Inclusive Care for the Elderly (PACE), Medicaid Fee-For-Service, and Medicaid Managed Care Programs for Years 2020 and 2021. Federal Register. 2019.
7. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
8. Office of Inspector General, U.S. Department of Health and Human Services. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Federal Register. 2020.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022.
10. American Medical Association. CPT Code Changes 2024: Obesity and Weight Management Services. 2024.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
12. National Council on Aging. Medicare Part D Coverage Gaps and the Treat and Reduce Obesity Act. Policy Brief. 2024.
13. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
14. Kaiser Family Foundation. Medicaid Coverage of GLP-1 Medications for Obesity: State-by-State Analysis. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Saxenda is a registered trademark of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medicare and Medicaid are registered trademarks of the U.S. Department of Health and Human Services. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.